Use of concurrent chemoradiation in advanced staged (T4) laryngeal cancer

详细信息    查看全文

• 作者：Cameron C. Wick ; MD^a ; Rod P. Rezaee ; MD^b ; Tammy Wang ; MD^b ; Andrea M. Garcia-Jarchow ; MD^c ; Chad A. Zender ; MD^b ; Michael Gibson ; MD ; PhD^d ; Min Yao ; MD^e ; Pierre Lavertu ; MD^b ; ^{Pierre.Lavertu@uhhospitals.org}
• 刊名：American Journal of Otolaryngology
• 出版年：2017
• 出版时间：January-February 2017
• 年：2017
• 卷：38
• 期：1
• 页码：72-76
• 全文大小：231 K
• 卷排序：38

文摘

Patients with advanced laryngeal cancer sometimes desire organ preservation protocols even if it portends a worse outcome.BackgroundTo assess outcomes of patients with T4 laryngeal cancer treated with chemoradiation therapy.MethodsCase series with chart review at a tertiary university hospital. Twenty-four patients with T4 laryngeal cancer all declined total laryngectomy with adjuvant radiation as the primary treatment modality and alternatively received concurrent chemoradiation therapy. The primary outcome was overall survival. Secondary outcomes were rates of tracheotomy dependence, gastric tube dependence, and need for salvage laryngectomy.ResultsAll patients had T4 laryngeal disease, 71% had cartilage invasion and 59% had regional metastasis to the neck. Kaplan–Meier analysis determined 2-year and 5-year overall survival to be 64% and 59% respectively. The locoregional recurrence rate was 25%. The distant metastasis rate was 21%. The rate of salvage laryngectomy was 17%, which occurred at a mean of 56.5 months after the original diagnosis. The rate of tracheotomy dependence was 33% while gastric tube dependence was 25%.ConclusionAdvanced T4 laryngeal cancer, particularly with cartilage invasion, remains a surgical disease best treated with total laryngectomy and adjuvant radiation. This data may help guide patients and practitioners considering concurrent chemoradiation therapy for definitive treatment of advanced laryngeal cancer.